Last reviewed · How we verify

NCT06548594

Out of State - tAN hEDS

Completed NA Last updated 27 February 2026
What this trial tests

NA trial testing Transcutaneous Auricular Neurostimulation in Hypermobile EDS (hEDS) in 30 participants. Completed in 29 March 2026.

Timeline
27 November 2024
Primary endpoint
1 April 2026
29 March 2026

Quick facts

Lead sponsorMedical University of South Carolina
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment30
Start date27 November 2024
Primary completion1 April 2026
Estimated completion29 March 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Medical University of South Carolina

Who can join

Adults 18 to 65, any sex, with Hypermobile EDS (hEDS). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hypermobile EDS and hypermobile spectrum disorder (collectively referred to as hEDS) are estimated to affect 1 in 500 individuals worldwide. hEDS patients have limited treatment options for their numerous symptoms that impact the quality of life. This clinical trial tests a new ear stimulation method in hEDS patients to determine if it may improve quality of life.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Transcutaneous Auricular Neurostimulation

Trials testing the same drug.

Other Medical University of South Carolina trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06548594.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing